Todos Medical Ltd. announced biomarker data from its majority-owned joint venture 3CL Pharma Ltd.'s Phase 2 clinical trial of Tollovir in hospitalized COVID-19 patients. The data showed a positive correlation between the clinical data announced for Tollovir on January 27, 2022 and biomarkers associated with acute phase immune response, inflammation, blood clotting and immune response to COVID-19. Additionally, renal and hepatic biomarker data showed no signals of treatment-associated risk with Tollovir therapy.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.000001 USD | 0.00% | 0.00% | -99.50% |
1st Jan change | Capi. | |
---|---|---|
-99.50% | 3.32K | |
-20.45% | 10.82B | |
+43.17% | 3.25B | |
-35.86% | 2.11B | |
-17.21% | 2.08B | |
-29.81% | 1.48B | |
+17.56% | 1.02B | |
-4.37% | 733M | |
-37.00% | 391M | |
-46.94% | 383M |
- Stock Market
- Equities
- TOMDF Stock
- News Todos Medical Ltd.
- Todos Medical Ltd. Announces Positive Biomarker Data from Phase 2 Trial of Tollovir in Hospitalized COVID-19 Patients